


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1 – 82. (Cancelled)

83. (New) A compound of Formula II or a pharmaceutically acceptable salt thereof:



wherein

X and Y are N,

Z is O;

Ar¹ is 2-pyridyl;

Ar² is phenyl;

and wherein

at least one of the Ar¹ and Ar² moieties are substituted with one or more moieties selected from the group consisting of -F, -Cl, -Br, -I, -SR, -SOR, -SO₂R, -SO₂NRR', -OCOR, -OCONRR', -NRCOR', -NRCO₂R', -CN, -CO₂R, -CONRR', -C(O)R, -CH(OR)R', -CH₂(OR), CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, and aryl;

R and R' are independently selected from the group consisting of H, CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, aryl;

R and R' may combine to form a ring;

with the proviso that the compound is not 3-(2-Pyridyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole or 3-(2-Pyridyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole.

84. (New) The compound according to claim 83, wherein Ar² is substituted with one or more moieties selected from the group consisting of CF₃, Cl, F, Br, SCH₃, and CN.

85. (New) The compound according to claim 83, wherein Ar¹ is substituted with one or more moieties selected from the group consisting of CF₃, Cl, F, Br, SCH₃, and CN.

86. (New) The compound according to claim 83, wherein each of Ar¹ and Ar² is substituted with one or more moieties selected from the group consisting of CF₃, Cl, F, Br, SCH₃, and CN.

87. (New) The compound according to claim 86, wherein the compound is one selected from the group consisting of:

3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59),

3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60),

3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61),

3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B83),

3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-chlorophenyl)-1,2,4-oxadiazole (B84),

3-(5-Chloropyrid-2-yl)-5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazole (B85),

3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-chlorophenyl)-1,2,4-oxadiazole (B87),

and pharmaceutically acceptable salts thereof.

88. (New) The compound according to claim 86, wherein the compound is one selected from the group consisting of:

3-(2-pyridyl)-5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazole (B28),

3-(5-chloropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B29)

3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30),

3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31),

3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32),

3-(2-pyridyl)-5-(2,5,6-trifluorophenyl)-1,2,4-oxadiazole (B45),

and pharmaceutically acceptable salts thereof.

89. (New) The compound according to claim 86, wherein the compound is one selected from the group consisting of:

3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30),

3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31),

3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32),

3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59),

3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60),


3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61),

and pharmaceutically acceptable salts thereof.

90. (New) The compound according to claim 89, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30) or a pharmaceutically acceptable salt thereof.

91. (New) The compound according to claim 89, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31) or a pharmaceutically acceptable salt thereof.

92. (New) The compound according to claim 89, wherein the compound is 3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32) or a pharmaceutically acceptable salt thereof.
93. (New) The compound according to claim 89, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59) or a pharmaceutically acceptable salt thereof.
94. (New) The compound according to claim 89, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60) or a pharmaceutically acceptable salt thereof.
95. (New) The compound according to claim 89, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61) or a pharmaceutically acceptable salt thereof.
96. (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula II or a pharmaceutically acceptable salt thereof:



wherein

X and Y are N,

Z is O;

Ar¹ is 2-pyridyl;

Ar² is phenyl;

and wherein

at least one of the Ar¹ and Ar² moieties are substituted with one or more moieties selected from the group consisting of -F, -Cl, -Br, -I, -SR, -SOR, -SO₂R, -SO₂NRR', -OCOR, -OCONRR', -NRCOR', -NRCO₂R', -CN, -CO₂R, -CONRR', -C(O)R, -CH(OR)R', -CH₂(OR), CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, and aryl;

R and R' are independently selected from the group consisting of H, CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, aryl;

R and R' may combine to form a ring;

with the proviso that the compound is not 3-(2-Pyridyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole or 3-(2-Pyridyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole.

97. (New) The pharmaceutical composition according to claim 96, wherein the compound or pharmaceutically acceptable salt thereof is one selected from the group consisting of:

3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30),

3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31),

3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32),

3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59),

3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60),

3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61),

and pharmaceutically acceptable salts thereof.

98. (New) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30) or a pharmaceutically acceptable salt thereof.

99. (New) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31) or a pharmaceutically acceptable salt thereof.
100. (New) The pharmaceutical composition according to claim 97, wherein the compound is 3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32) or a pharmaceutically acceptable salt thereof.
101. (New) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59) or a pharmaceutically acceptable salt thereof.
102. (New) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60) or a pharmaceutically acceptable salt thereof.
103. (New) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61) or a pharmaceutically acceptable salt thereof.
104. (New) A method for treating a disease associated with Group I mGluR activation comprising the step of administering to a patient in need of such treatment a compound or pharmaceutically acceptable salt thereof according to claim 1.
105. (New) The method according to claim 104, wherein the disease is a neurological disease.
106. (New) The method according to claim 104, wherein the disease is a psychiatric disease.
107. (New) The method according to claim 104, wherein the disease is selected from the group consisting of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease.

108. (New) The method according to claim 104, wherein the compound or pharmaceutically acceptable salt thereof is one selected from the group consisting of:

- 3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30),
- 3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31),
- 3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32),
- 3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59),
- 3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60),
- 3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61),

and pharmaceutically acceptable salts thereof.

109. (New) A method for treating a disease associated with Group I mGluR activation, comprising the step of administering to a patient in need of such treatment a pharmaceutical composition according to claim 96.

110. (New) The method according to claim 109, wherein the disease is a neurological disease.

111. (New) The method according to claim 109, wherein the disease is a psychiatric disease.

112. (New) The method according to claim 109, wherein the disease is selected from the group consisting of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease.

113. (New) The method according to claim 109, wherein the compound or pharmaceutically acceptable salt thereof is one selected from the group consisting of:

- 3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30),

3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31),

3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32),

3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59),

3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60),

3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61),

and pharmaceutically acceptable salts thereof.

114. (New) A pharmaceutical composition that is obtained by the process of combining a pharmaceutically acceptable excipient with a compound or a pharmaceutically acceptable salt thereof according to claim 1.